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Abstract
Introduction: The present study assessed the potential functions of interleukin (IL)-32a on inflammatory arthritis
and endotoxin shock models using IL-32a transgenic (Tg) mice. The potential signaling pathway for the IL-32-
tumor necrosis factor (TNF)a axis was analyzed in vitro.
Methods: IL-32a Tg mice were generated under control of a ubiquitous promoter. Two disease models were used
to examine in vivo effects of overexpressed IL-32a: Toll-like receptor (TLR) ligand-induced arthritis developed using
a single injection of lipopolysaccharide (LPS) or zymosan into the knee joints; and endotoxin shock induced with
intraperitoneal injection of LPS and D-galactosamine. TNFa antagonist etanercept was administered simultaneously
with LPS in some mice. Using RAW264.7 cells, in vitro effects of exogenous IL-32a on TNFa, IL-6 or macrophage
inflammatory protein 2 (MIP-2) production were assessed with or without inhibitors for nuclear factor kappa B
(NFB) or mitogen-activated protein kinase (MAPK).
Results: Single injection of LPS, but not zymosan, resulted in development of severe synovitis with substantial
articular cartilage degradation in knees of the Tg mice. The expression of TNFa mRNA in inflamed synovia was
highly upregulated in the LPS-injected Tg mice. Moreover, the Tg mice were more susceptive to endotoxin-
induced lethality than the wild-type control mice 48 hours after LPS challenge; but blockade of TNFa by
etanercept protected from endotoxin lethality. In cultured bone marrow cells derived from the Tg mice,
overexpressed IL-32a accelerated production of TNFa upon stimulation with LPS. Of note, exogenously added IL-
32a alone stimulated RAW264.7 cells to express TNFa, IL-6, and MIP-2 mRNAs. Particularly, IL-32a -induced TNFa,
but not IL-6 or MIP-2, was inhibited by dehydroxymethylepoxyquinomicin (DHMEQ) and U0126, which are specific
inhibitors of nuclear factor kappa B (NFB) and extracellular signal regulated kinase1/2 (ERK1/2), respectively.
Conclusions: These results show that IL-32a contributed to the development of inflammatory arthritis and
endotoxin lethality. Stimulation of TLR signaling with LPS appeared indispensable for activating the IL-32a-TNFa
axis in vivo. However, IL-32a alone induced TNFa production in RAW264.7 cells through phosphorylation of
inhibitor kappa B (IB) and ERK1/2 MAPK. Further studies on the potential involvement of IL-32a-TNFa axis will be
beneficial in better understanding the pathology of autoimmune-related arthritis and infectious immunity.
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Introduction
Interleukin-32 (IL-32) was originally identified as natural
killer (NK) transcript 4, which is induced by IL-18 in
NK cells [1]. NK transcript 4 showed cytokine-like char-
acteristics and played a critical role in inflammation and
was therefore renamed IL-32. This cytokine is reportedly
produced by NK cells, T cells, epithelial cells, mono-
cytes, and fibroblasts after stimulation by IL-2, IL-12,
and IL-18 and interferon-gamma [2]. Initially, four iso-
forms of IL-32 (IL-32a, b, g, and δ) derived from alter-
native splicing of a single gene. Among these, IL-32a is
the shortest transcript, whereas IL-32 g is the longest
isoform and has the strongest biological activity [2,3].
Two additional isoforms, IL-32ε and ζ, have recently
been identified, but these isoforms are not ubiquitously
expressed except in T cells [4].
IL-32 has been shown to exhibit properties typical of a
proinflammatory cytokine and to drive the induction of
other proinflammatory cytokines and chemokines, such as
tumor necrosis factor-alpha (TNFa) and IL-1, IL-6, and
IL-8. Owing to such proinflammatory properties, IL-32
has been considered to play a key role in the development
of various inflammatory diseases, including rheumatoid
arthritis (RA), inflammatory bowel disease [5], mycobac-
terial [6,7] or viral [8-10] infection, chronic obstetric pul-
monary disease [11], and pancreatic tumor [12,13].
Although no receptor or analog of IL-32 has yet been
identified in mice, human IL-32 reportedly exerts proin-
flammatory effects as an inducer of TNFa and other
inflammatory cytokines in mice both in vitro and in vivo
[2,14-16].
During the last decade, TNFa and IL-6 became widely
perceived as substantial therapeutic targets in RA given
that the use of either anti-TNFa or anti-IL-6 therapy
could successfully control chronic inflammation in RA.
As IL-32 is capable of inducing TNFa and IL-6, this cyto-
kine is increasingly becoming a focus as a potential thera-
peutic target in RA and other inflammatory disorders.
Mounting evidence regarding upstream signaling regula-
tors for IL-32 production has been accumulating in the
literature [12,17-20]. However, signaling pathways that
are downstream of IL-32 and that lead to TNFa produc-
tion have yet to be fully elucidated. Most investigators
advocate the position that IL-32 augments Toll-like
receptor (TLR) signaling, and TLR-2, -3, and -4 are asso-
ciated with the effects of IL-32 signaling, although the
detailed mechanisms remain to be clarified. Only a few
studies to date have reported the implications of mito-
gen-activated protein kinase (MAPK) or nuclear factor
kappa B (NF-B) pathways in IL-32 signaling [2,21-23].
The present study generated IL-32a transgenic (Tg)
mice that overexpressed human IL-32a under a control
of ubiquitous CAG promoter, and it assessed the in vivo
effects of IL-32a on TLR signaling in the induction of
arthritis and endotoxin shock models using the Tg mice.
In addition, the potential signaling pathway of the IL-
32a-TNFa axis was analyzed in vitro.
Materials and methods
Reagents
Lipopolysaccharide (LPS) from Escherichia coli 0111:B4
and zymosan A from Saccharomyces cerevisiae were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA), and
D-galactosamine was purchased from Wako Pure Chemi-
cal Industries (Osaka, Japan). Etanercept was obtained
from Wyeth (Tokyo, Japan). Recombinant human IL-32a
protein (rIL-32a) was obtained from Takara Bio (Shiga,
Japan). IL-32a-specific enzyme-linked immunosorbent
assay (ELISA) (Human IL-32a ELISA MAX Deluxe Set)
was purchased from BioLegend (San Diego, CA, USA),
and TNFa-specific ELISA (Quantikine Mouse TNFa)
and anti-IL-32a antibody were purchased from R&D Sys-
tems (Minneapolis, MN, USA). All other antibodies were
purchased from Cell Signaling Technology Japan (Tokyo,
Japan). Dehydroxymethylepoxyquinomicin (DHMEQ)
(an inhibitor for NF-B) was provided as previously
described [24,25]. MAPK inhibitors U0126, SB203580,
and SP600125 - which are inhibitors for ERK1/2, p38,
and JNK, respectively - were purchased from Sigma-
Aldrich. DHMEQ and MAPK inhibitors were dissolved
in 100% dimethyl sulfoxide (DMSO) at 100 mg/mL and
were stored in aliquots at -30°C. Before use in cell cul-
ture, they were diluted with the medium to a final
DMSO concentration of not more than 0.05%.
Real-time polymerase chain reaction analysis
Total RNAs were isolated from each sample by RNAiso
plus (Takara Bio), and cDNAs were synthesized from total
RNAs by using a PrimeScript RT reagent Kit (Takara Bio).
Real-time polymerase chain reaction (PCR) was performed
by using SYBR Premix ExTaq II (Takara Bio) with a DICE
Thermal cycler (Takara Bio) in accordance with the
instructions of the manufacturer. Results were normalized
to glyceraldhyde-3-phosphate dehydrogenase (GAPDH) as
the fold change compared with samples. The primer
sequences used in this study are presented in Table 1.
Immunoblot analysis
Mice organs or cell lysates were prepared by using RIPA
buffer: 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.5, 5 mM
ethylenediaminetetraacetic acid (EDTA), and a protease
inhibitor cocktail. An equal volume of protein from each
lysate was separated by SDS-PAGE, and separated pro-
teins were transferred to nitrocellulose membranes. After
transfer, the membrane was blocked with 5% non-fat
dried skim milk for 1 hour at room temperature and
then incubated with the primary antibody against the
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target molecule overnight. Next, the membrane was incu-
bated with horseradish peroxidase-conjugated secondary
antibody for 1 hour at room temperature. After washing,
protein was detected by using an enhanced chemilumi-
nescence (ECL) system. The same membrane was then
stripped by Tris-HCL (62.5 mM), 2% SDS, and b-mer-
captoethanol and blocked with skim milk and incubated
with primary antibody against another molecule, follow-
ing the same procedure mentioned above.
Generation of human IL-32a transgenic mice
We generated IL-32a Tg mice, which overexpressed
human IL-32a under a control of a ubiquitous CAG
promoter constructed by the first intron of the chicken
b-actin gene and a portion of the rabbit b-globin gene
[26]. The background of these mice was C57BL/6 Jcl
(obtained from CLEA Japan, Tokyo, Japan). Wild-type
C57BL/6 Jcl (Wt) mice were also obtained from CLEA
Japan. All mice were 18 to 20 weeks old when they
were used. All animal experiments were conducted in
accordance with institutional and national guidelines.
IL-32a insertion was confirmed by amplification of the
genome DNA isolated from mouse organs by using real-
time PCR. The reason real-time PCR was employed was
that we wanted to simultaneously detect and quantify
transgene-derived IL-32a in multiple organs of Tg mice.
The amount of TNFa expression in multiple organs was
measured by real-time PCR. IL-32a protein in multiple
organs was detected by immunoblot analysis. Levels of
IL-32a in blood serum, knee, and liver lysate were mea-
sured by specific ELISA.
Inflammatory arthritis model
Inflammatory arthritis was induced as described pre-
viously [27-29]. As in these reports, intra-articular injec-
tion of LPS was employed in IL-32a Tg mice to elucidate
the arthritogenic capacity of IL-32a. Knees of Tg and Wt
mice were injected once with LPS (1 μg, much less than
the reported amount [27,28]) or zymosan (20 μg, much
less than the reported amount [29]) without any other
material as a booster. Injection of phosphate-buffered sal-
ine (PBS) served as a control to the contralateral knee of
the same mouse. Two weeks after injection, a histopatho-
logical examination was performed, and TNFa mRNA
expression in synovia of knees was quantitatively mea-
sured by using real-time PCR.
Endotoxin shock model
Endotoxin shock was induced by intraperitoneal injec-
tions of 5 μg of LPS and 10 mg of D-galactosamine [30].
Half of the mice were injected with 100 μg of etanercept
at the same time. All injected mice were closely moni-
tored every hour for the first 16 hours and every 3 to 6
hours thereafter for 48 hours. In an additional experi-
ment, we sacrificed mice at 1, 3, and 6 hours after intra-
peritoneal injection and extracted the liver, spleen, and
blood serum. TNFa mRNA of liver and spleen lysates
was measured by real-time PCR, and serum TNFa was
measured by ELISA.
Cell culture
Bone marrow (BM) was extracted from the leg bones of
Tg or Wt mice and cultured for 72 hours in alpha-mini-
mum essential medium (Sigma-Aldrich) containing 10%
fetal calf serum (FCS), 100 U/mL penicillin, 100 mg/mL
streptomycin, and 1% Gluta Max (Gibco Invitrogen,
Carlsbad, CA, USA) supplemented with macrophage col-
ony-stimulating factor (50 ng/mL; Kyowa Hakko Kirin,
Tokyo, Japan). RAW 264.7 cells were cultured in Dulbec-
co’s modified Eagle’s medium (high-glucose) (Gibco Invi-
trogen) containing 10% FCS, 100 U/mL penicillin, and
100 μg/mL streptomycin.
Stimulation of cells
BM cells from Tg and Wt mice (106 cells) were incubated
under stimulation of LPS (50 ng/mL) for 1, 3, 6, and 24
hours, and the amount of TNFa was measured by real-
time PCR. TNFa concentration in culture media of BM
cells (105 cells) after 24-hour incubation with LPS (5, 10,
or 50 ng/mL) was measured by specific ELISA. RAW
264.7 cells (2 × 104 cells) were cultured with rIL-32a or
LPS for 24 hours, and the TNFa concentration in culture
media was measured by ELISA. For the analysis of signal-
ing pathway, RAW 264.7 cells (2 × 104 cells) were stimu-
lated with rIL-32a in combination with the specific
inhibitors of NF-B and MAPKs, such as DHMEQ (0.4,
2, or 10 μg/mL), U0126 (0.2, 1, or 5 μM), SB203580 (0.2,
1, or 5 μM), and SP600125 (0.4, 2, or 10 μM). DMSO
(final concentration of 0.05%) served as a control. After
24 hours of culture, the level of TNFa in culture media
was measured by ELISA. For immunoblot analysis, RAW
264.7 cells (2 × 106 cells) were cultured with rIL-32a for
Table 1 Primers used in real-time polymerase chain
reaction
Primer Sense Sequence
Mouse GAPDH Forward 5’-CTTTGTCAAGCTCATTTCCTGG-3’
Reverse 5’-TCTTGCTCAGTGTCCTTGC-3’
Human IL-32a Forward 5’-CCTTGGCTCCTTGAACTTTTG-3’
Reverse 5’-CTGTCCACGTCCTGATTCTG-3’
Mouse TNFa Forward 5’-CTTCTGTCTACTGAACTTCGGG-3’
Reverse 5’-CAGGCTTGTCACTCGAATTTTG-3’
Mouse IL-6 Forward 5’-CAAAGCCAGAGTCCTTCAGAG-3’
Reverse 5’-GTCCTTAGCCACTCCTTCTG-3’
Mouse MIP-2 Forward 5’-GAAGTCATAGCCACTCTCAAGG-3’
Reverse 5’-CTTCCGTTGAGGGACAGC-3’
GAPDH, glyceraldhyde-3-phosphate dehydrogenase; IL, interleukin; MIP-2,
macrophage inflammatory protein 2; TNFa, tumor necrosis factor-alpha.
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5, 10, 30, 60, 90, 120, or 180 minutes, followed by wash-
ing with ice-cold PBS and lysis in RIPA detergent buffer.
The resultant cell lysates were then immunoblotted by
using affinity-purified antibodies against phospho-IB,
IB, phospho-ERK1/2, ERK1/2, phospho-p38, p38, phos-
pho-JNK, JNK, and b-actin. mRNA expressions for IL-6
and macrophage inflammatory protein 2 (MIP-2) as well
as TNFa in IL-32-stimulated RAW 264.7 cells (2 × 104
cells) were measured by real-time PCR, and the inhibi-
tory effects of specific signaling inhibitors, including
DHMEQ, U0126, SB203580, and SP600125, were
analyzed.
Statistical analysis
Results are reported as the mean ± standard deviation.
Statistical analysis was undertaken by using a two-tailed
Student t test. Differences were considered statistically
significant at a P value of less than 0.05. The endotoxin
shock model was graphed in Kaplan-Meier format and
analyzed by a log-rank test. All experiments were per-
formed in three or four times.
Results
Generation of human IL-32a transgenic mice
Human IL-32a Tg mice were designed to overexpress
human IL-32a by using CAG promoter. Of seven F0
mice, two mice expressing sufficient levels of IL-32a
mRNA were used to establish lines. The F0 mice and all
offspring exhibited no evident pathological phenotype,
had a normal body weight, and developed and bred nor-
mally. Real-time PCR analysis of the Tg mouse lines
demonstrated high levels of IL-32a mRNA expression in
a variety of organs, prominently in the knee joint and car-




Figure 1 Overexpression of transgene-derived interleukin-32 alpha (IL-32a) in transgenic (Tg) mice. Levels of transgene-derived human
IL-32a mRNA in various organs were measured by real-time polymerase chain reaction. IL-32a mRNA expression was prominent in knee joints
and heart (a). Transgene-derived IL-32a protein was not detected in serum from Tg mice (b) but was detected in multiple organs (c). Levels of
tumor necrosis factor-alpha (TNFa) mRNA constitutively expressed in various organs were analyzed for Tg and wild-type (Wt) mice. The relative
quantities of Tg were divided by those of Wt of each organ and that ratio is graphed (d). In particular, TNFa expression levels in colon and knee
joint of Tg mice corresponded to six- to seven-fold those of their littermates. The values are expressed as the mean ± standard deviation for
four different mice. GAPDH, glyceraldhyde-3-phosphate dehydrogenase.
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protein could be detected in multiple organs (Figure 1b,
c) but not in serum from Tg mice (Figure 1b). This result
might be because the IL-32a isotype has been reported
to remain intracellularly [2]. Constitutive expression of
TNFa mRNA induced by overexpressed IL-32a was
apparent in most organs, and expression levels in the
colon and knee joint from Tg mice reached six to seven
times the levels seen in littermates (Figure 1d).
Single intra-articular injection of LPS, but not zymosan,
induced inflammatory synovitis and cartilage degradation
in transgenic mice
Mice were sacrificed 2 weeks after a single injection of
LPS or zymosan, followed by a histopathological exami-
nation of the knee joints. The results indicated that the
single injection of LPS, but not zymosan, resulted in the
development of severe synovitis with articular cartilage
destruction in the knees of Tg mice. Such LPS-induced
arthritis did not occur in the knees of Wt mice or in
contralateral knees injected with PBS (Figure 2a). The
level of TNFa mRNA expressed in inflamed synovia
after LPS injection was significantly higher in Tg mice
than in Wt mice (Figure 2b).
Transgenic mice exhibited severe endotoxin lethality after
LPS challenge
As a single intraperitoneal injection of LPS with D-galac-
tosamine has been perceived to be capable of inducing
endotoxin shock in mice, the impacts of constitutive
expression of IL-32a and subsequently produced TNFa
on endotoxin lethality were investigated. Mice receiving
an intraperitoneal injection of LPS started to die in
5 hours, and the survival rates at 48 hours after injection
were 41% for Tg mice and 75% for Wt mice (Figure 3a),
showing statistical significance (P < 0.05). Importantly,
blockade of TNFa by simultaneous administration of eta-
nercept protected from endotoxin shock and markedly
increased survival rate in both Tg and Wt mice, suggest-
ing that IL-32-induced TNFa played a key role in devel-
oping endotoxin shock. TNFa mRNA expression in liver
and spleen peaked at 1 hour after injection and at much
higher levels than those of Wt mice (P < 0.01) (Figure 3b,
c). A similar temporal course was observed for the level
of TNFa protein in serum (Figure 3d). At 1 hour after
injection, levels of TNFa mRNA in the liver and spleen
and TNFa protein in serum were significantly higher in
Tg mice than in Wt mice (P < 0.05).
A B 
Figure 2 Inflammatory arthritis induced by single intra-articular injection of lipopolysaccharide (LPS) in transgenic (Tg) mice. One
microgram of LPS or 20 μg of zymosan was injected into the knee joints of Tg and wild-type (Wt) mice. Histopathologically, severe synovitis
with articular cartilage destruction was observed 2 weeks after injection in Tg mice injected with LPS but not in Tg mice injected with zymosan
or phosphate-buffered saline or in Wt mice (×100) (a). The level of tumor necrosis factor-alpha (TNFa) mRNA expressed in inflamed synovia was
significantly higher in Tg mice injected with LPS than in Tg mice injected with zymosan or in Wt mice injected with LPS (*P < 0.01) (b). The
values are expressed as the mean ± standard deviation for four different mice. GAPDH, glyceraldhyde-3-phosphate dehydrogenase.
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Endogenously overexpressed IL-32a accelerated
production of TNFa upon stimulation with LPS
To examine the effects of endogenous IL-32a on TNFa
production in vitro, BM macrophages derived from IL-32a
Tg and Wt mice were used. The level of TNFa mRNA
expression was significantly higher in Tg mice than in Wt
mice after stimulation with LPS (P < 0.05). Temporal
changes in TNFa mRNA expression revealed that the level
of TNFa mRNA peaked at 3 hours after LPS stimulation
and gradually decreased with time (Figure 4a). LPS
increased TNFa secretion into culture media in a dose-
dependent manner, and the amounts of TNFa produced by
BM macrophages were universally higher in Tg mice than
in Wt mice throughout all doses of LPS tested (Figure 4b).
Exogenous IL-32a enhanced TNFa production in RAW
264.7 cells through NF-B and ERK1/2 signaling pathways
To elucidate the effects of exogenous IL-32a on TNFa
production in vitro, rIL-32a was added to RAW 264.7
cells in culture. Although RAW 264.7 cells constitutively
produced substantial amounts of TNFa, rIL-32a alone as
well as LPS could further stimulate RAW 264.7 cells to
produce TNFa (Figure 5a). DHMEQ and U0126, as inhi-
bitors of NF-B and ERK1/2, respectively, reduced IL-
32a-induced TNFa production in a dose-dependent
manner, whereas SB203580 and SP600125, as inhibitors
of p38 and JNK, respectively, did not (Figure 5b). Immu-
noblot analysis revealed that exogenous IL-32a clearly
phosphorylated IB and ERK1/2, both starting at 30 min-
utes and peaking at 90 minutes for ERK1/2 and at 120
minutes for IB, whereas significant phosphorylation was
not observed in p38 or JNK (Figure 5c). These results
supported the finding that DHMEQ and U0126, but not
SB203580 and SP600125, inhibited IL-32a-induced
TNFa production. Consequently, exogenous IL-32a-
induced TNFa production was mediated predominantly




Figure 3 Interleukin-32 alpha overexpression in mice increased the lethality of lipopolysaccharide (LPS)-induced endotoxin shock.
Endotoxin shock was induced in both transgenic (Tg) mice (n = 24) and wild-type (Wt) mice (n = 24) by intraperitoneal injection of LPS with D-
galactosamine. Twelve mice of each group were simultaneously administered etanercept. All mice were monitored for survival up to 48 hours.
Survival rate was significantly worse in the Tg group than in the Wt group (*P < 0.05). Etanercept protected against endotoxin shock in both
groups (a). Temporal changes in TNFa levels were measured by real-time polymerase chain reaction for liver and spleen lysate or. enzyme-linked
immunosorbent assay for blood serum. Levels of tumor necrosis factor-alpha (TNFa) mRNA and protein peaked at 1 hour after LPS injection in
the liver (b), spleen (c), and serum (d) from Tg and Wt mice, but levels were much higher in Tg mice than in Wt mice (*P < 0.05, **P < 0.01).
The values are expressed as the mean ± standard deviation for four different mice. GAPDH, glyceraldhyde-3-phosphate dehydrogenase.
Nakayama et al. Arthritis Research & Therapy 2012, 14:R120
http://arthritis-research.com/content/14/3/R120
Page 6 of 11
Exogenous IL-32a stimulated IL-6 and MIP-2 expression in
RAW 264.7 cells independently of NF-B and MAPK
signaling pathways
The effects of exogenous IL-32a on IL-6 and MIP-2
production were examined since these cytokines were
reportedly induced by IL-32 [3]. rIL-32a alone stimu-
lated RAW 264.7 cells to express TNFa, IL-6, and MIP-
2 mRNAs to a similar degree. Specific signaling inhibi-
tors, DHMEQ and U0126, suppressed the expression of
TNFa mRNAs; however, neither of these two inhibitors
affected the expression of IL-6 and MIP-2 mRNAs
induced by IL-32a (Figure 6), suggesting that a signaling
pathway other than NF-B and MAPKs might be
involved in IL-6 and MIP-2 mRNA expressions.
Discussion
To date, the arthritogenic role of IL-32 has been eluci-
dated on the basis of accumulated evidence that overex-
pression of IL-32b in a mouse model using bone
transplantation exacerbated collagen-induced arthritis in
mice [14] and that intra-articular injection of IL-32g in
mouse knee joints resulted in severe joint inflammation
[15]. In this study, although IL-32a Tg mice did not
spontaneously exhibit any abnormal phenotype, intra-
articular injection of low-dose LPS resulted in the devel-
opment of inflammatory arthritis. However, injection of
zymosan was not capable of sufficiently inducing TNFa
and subsequent arthritis. As LPS is known as a specific
ligand of TLR-4, interaction of IL-32a with TLR-4 may
play a critical role in the development of arthritis, and
this was also the case in LPS-triggered endotoxin shock
in the Tg mice. This endotoxin shock model provided
an excellent means to evaluate the effects of IL-32a on
infectious immunity. In the present study, IL-32a over-
production in Tg mice was associated with severe endo-
toxin lethality; this was shown to be mediated through
the induction of TNFa, because etanercept significantly
attenuated the endotoxin shock.
Although the present study clearly demonstrated that
LPS, as a TLR-4 agonist, but not the TLR-2 agonist
zymosan, might play a key role in potentiating the
proinflammatory activity of IL-32a, how exactly IL-32a
interacted with the TLR-4 signaling pathway remains
unclear. Most recently, Heinhuis and colleagues [31]
reported that LPS co-stimulation was mandatory to eli-
cit IL-32 bioactivity in THP-1 cells, and the present
study obtained similar findings that TNFa production
promoted by IL-32a required co-stimulation with LPS
(Figure 4). In terms of the interaction between IL-32
and TLR-2/NOD2 (nucleotide-binding oligomerization
domain-containing protein 2) signaling, IL-32 has been
reported to stimulate TNFa, IL-6, and IL-8 production
by directly increasing expression of TLR-2 and NOD2
[32]. Conversely, the interaction of IL-32 with TLR-4
A B 
Figure 4 Bone marrow (BM) macrophages from transgenic (Tg) mice were stimulated to produce tumor necrosis factor-alpha (TNFa)
upon stimulation with lipopolysaccharide (LPS). Temporal changes in the level of TNFa mRNA expressed by BM macrophages were
measured upon stimulation with LPS. TNFa mRNA level peaked at 3 hours and gradually decreased and was significantly higher in Tg mice than
in wild-type (Wt) mice over time (a). The amount of TNFa in culture media was measured after 24 hours of LPS stimulation by using a specific
enzyme-linked immunosorbent assay (b). LPS stimulated secretion of TNFa from BM macrophages in a dose-dependent manner, and levels were
higher in Tg mice than in Wt mice (*P < 0.05). The values are expressed as the mean ± standard deviation for three different mice. GAPDH,
glyceraldhyde-3-phosphate dehydrogenase.
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can be speculated to involve the binding of IL-32 to its
putative receptor modulates downstream signaling for
TLR-4 or other TLRs, since the proinflammatory activ-
ities of IL-32 were present even in macrophages derived
from TLR-4-/- mice, and stimulation with IL-32 plus
TLR ligand elicited only additive effects rather than
synergistic effects [33]. Two candidate molecules poten-
tially connecting IL-32a and TLR-4 signaling are con-
sidered. One is proteinase-3 and the other is proteinase-
activated receptor 2 (PAR2); the former reportedly acts
as an IL-32-binding protein and cleaves all isoforms of
IL-32 to generate a more active form [34,35], and the
latter has been shown to be associated with late NF-B
activation and subsequent TNFa production predomi-
nantly through a myeloid differentiation factor 88
(MyD88)-independent pathway [36].
In contrast to mounting evidence on upstream signal-
ing regulators for IL-32, downstream signaling pathways
of IL-32 toward TNFa production have not yet been
analyzed in detail, and only a small number of reports
have focused on different signals in different cell types.
The first report of IL-32 advocated that IL-32a
A C 
B 
Figure 5 Exogenous ‘IL-32a induced’ TNFa production by RAW 264.7 cells through activation of NF-B and ERK1/2 MAPK. Two
different concentrations of rIL-32a or LPS were added to RAW 264.7 cells in culture, followed by incubation for 24 hours. The level of TNFa in
culture media was measured by a specific enzyme-linked immunosorbent assay (a). IL-32a alone as well as LPS was capable of inducing TNFa
secretion into culture media by RAW 264.7 cells. Values are expressed as ± standard deviation (SD) of four determinations. RAW 264.7 cells were
cultured with or without rIL-32a for 24 hours in combination with inhibitors for IB and MAPKs, including DHMEQ, U0126, SB203580, and
SP600125 (b). IL-32a-induced TNFa production was inhibited by DHMEQ or U0126 but not by SB203580 or SP600125 (*P < 0.05, **P < 0.01).
Values are expressed as ± SD of four determinations. Phosphorylations of IB and MAPKs in RAW 264.7 cells were determined by Western
blotting by using anti-phospho-IB, -ERK1/2, -p38, or -JNK antibodies after treatment with rIL-32a (100 ng/mL) (c). rIL-32a stimulated
phosphorylation of IB and ERK1/2, starting at 30 minutes and peaking at 90 (ERK1/2) or 120 (IB) minutes, whereas significant phosphorylation
was not observed in p38 or JNK. Degradation of IB was also observed with a peak at 90 minutes. These data represent one of three
independent experiments. DHMEQ, dehydroxymethylepoxyquinomicin; DMSO, dimethyl sulfoxide; IB, inhibitor kappa B; IL, interleukin; LPS,
lipopolysaccharide; MAPK, mitogen-activated protein kinase; NF-B, nuclear factor kappa B; rIL-32a, recombinant human interleukin-32a protein;
TNFa, tumor necrosis factor-alpha.
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stimulated TNFa production through activation of NF-
B and p38 MAPK in mouse RAW 267.4 cells; the two
peaks of p38 MAPK phosphorylation at 5 and 45 min-
utes were considered a characteristic finding for this
cytokine [2]. Netea and colleagues [21] subsequently
reported that IL-32-induced TNFa production by
human peripheral blood mononuclear cells (PBMCs)
was similarly regulated through phosphorylation of p38
MAPK. On the other hand, ERK1/2 MAPK was domi-
nant in IL-32-induced osteoclastogenesis for human
PBMCs [22] and in IL-32-induced IL-6 and IL-8 pro-
duction by human fibroblast-like synoviocytes [23]. The
present study demonstrated that IL-32a-induced TNFa
production was mediated through phosphorylation of
IB and ERK1/2 in RAW 267.4 cells. Actually, all three
components of MAPKs - p38, JNK, and ERK1/2 - were
constitutively phosphorylated in RAW 267.4 cells; how-
ever, only ERK1/2 phosphorylation was significantly
accelerated in response to IL-32a stimulation. This
observation corroborated the fact that the addition of
inhibitors for ERK1/2 and NF-B suppressed each phos-
phorylation (data not shown and Figure S1 of Additional
file 1) and consequently canceled IL-32a-induced upre-
gulation of TNFa at the mRNA level (Figures 5b and 6).
Given the delayed phosphorylation of IB and ERK1/2
starting at 30 minutes in this study, IL-32a in RAW
267.4 cells might not directly activate IB or ERK1/2.
Instead, other molecules might play an important role
A B 
C 
Figure 6 Exogenous IL-32a stimulated mRNA expression of IL-6 and MIP-2 independently of NF-B and MAPK signaling pathways.
RAW 264.7 cells were stimulated with rIL-32a in combination with inhibitors for IB and MAPKs, including DHMEQ, U0126, SB203580, and
SP600125, for 6 hours. The amounts of mRNA of TNFa (a), IL-6 (b), and MIP-2 (c) were measured by real-time polymerase chain reaction. rIL-32a
alone stimulated RAW 264.7 cells to express IL-6 and MIP-2 as well as TNFa at the mRNA level. None of the inhibitors canceled IL-6 and MIP-2
mRNA expression induced by IL-32a, whereas DHMEQ and U0126 suppressed TNFa mRNA expression. Values are expressed as mean ± standard
deviation of triplicate determinations. Ct, control; DHMEQ, dehydroxymethylepoxyquinomicin; GAPDH, glyceraldhyde-3-phosphate
dehydrogenase; IB, inhibitor kappa B; IL, interleukin; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MIP-2, macrophage
inflammatory protein 2; NF-B, nuclear factor kappa B; n.s., not significant; rIL-32a, recombinant human interleukin-32a protein; TNFa, tumor
necrosis factor-alpha.
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in IB or ERK1/2 activation of IL-32a, or the IL-32a-
TNFa axis might use the MyD88-independent pathway
reportedly associated with the late inflammatory
response of TLR-4 [37]. Our study also revealed that IL-
32a induced IL-6 and MIP-2 as well as TNFa, but their
induction was not canceled by inhibitors for NF-B or
MAPKs. This observation indicates that a signaling
pathway other than NF-kB or MAPKs might be involved
in IL-6 and MIP-2 expressions.
IL-32g Tg mice obtained by using a promoter similar
to that of the present study reportedly exhibited no
apparent phenotype, but once inflammatory colitis was
induced with dextran sodium sulfate (DSS) in the Tg
mice, severe colitis occurred within 4 days [38]. Interest-
ingly, at more than 6 days after DSS challenge, the
degree of colonic inflammation in the Tg mice was sig-
nificantly reduced, and recovery was more rapid than
that in Wt mice because of increased IL-10 levels in
serum. In another study, IL-32b was reported to pro-
mote the production of IL-10 in human cell lines [39].
According to our data on RAW 264.7 cells, the level of
TNFa in culture media peaked at 12 hours after stimu-
lation with IL-32a and gradually decreased thereafter,
whereas IL-10 levels increased from 24 to 96 hours after
stimulation (data not shown and Figure S2 of Additional
file 2). IL-32 is thus considered to represent a cytokine
possessing contradictory properties according to the dif-
ferent phases of the disease. Such paradoxical effects of
IL-32 were not observed in our Tg mice. In fact, a single
intra-articular injection of LPS in our Tg mice resulted
in a transient flare of inflammatory arthritis, character-
ized by neutrophil infiltration and synovial proliferation,
but such inflammation might cease within 2 weeks, fol-
lowed by amelioration of synovitis with only mild carti-
lage erosion remaining. On the other hand, the
endotoxin shock model using our Tg mice was suitable
for examining short-term effects, but not long-term
effects, of IL-32 in vivo since most mice died within sev-
eral hours after LPS challenge, and TNFa induced by
IL-32a and LPS was confirmed as an early mediator of
endotoxin lethality [40]. The time-dependent and com-
plicated regulation of IL-32 and the relevant molecules
of the IL-32-TNFa axis during the course of autoim-
mune-related arthritis and infectious immunity should
be elucidated in future studies.
Conclusions
This study revealed that IL-32a contributed to the
development of LPS-induced inflammatory arthritis and
endotoxin lethality; therefore, stimulation of LPS
appears indispensable for activating the IL-32-TNFa
axis in vivo. However, IL-32a alone induced TNFa pro-
duction in RAW 264.7 cells through phosphorylation of
IB and ERK1/2 MAPK.
Additional material
Additional file 1: Figure S1. Phosphorylation of IB and MAPKs
stimulated with rIL-32a (100 ng/ml) in RAW 264.7 cells was determined
by Western blotting using anti-phospho-IB, -ERK1/2, -p38, and -JNK
antibodies. Phosphorylation of IB and ERK1/2 were observed and
inhibited by their specific inhibitors, while significant phosphorylation of
p38 or JNK. was not observed. This data represents one of three
independent experiments.
Additional file 2: Figure S2. Levels of TNFa and IL-10 were expressed
as a proportion to that in control culture media without IL-32a
stimulation. Level of TNFapeaked at 12 h after stimulation with IL-32a
and gradually decreased thereafter, while levels IL-10 kept increasing
from 24 to 96 h after stimulation. Values are expressed as mean ± SD of
triplicate determinations.
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